Table 3.
Unadjusted efficacy and safety outcomes following all cycles of chemotherapy
| Outcomes over all cycles (median, range) | Cinvanti (n = 495) | Emend IV (n = 458) | Generic alternatives (n = 479) |
|---|---|---|---|
| Complete CINV response1: day 1 | 92.1% | 91.0% | 98.1% |
| Complete CINV response1: days 2 to 5 | 90.1% | 84.1% | 93.7% |
| Complete CINV response1: days 1 to 5 | 87.9% | 82.3% | 92.5% |
| Documented use of rescue therapy | 4.2% | 11.8% | 3.1% |
| Infusion site reactions | 0.4% (2) | 1.5% (7) | 1.2% (6) |
| Reaction grade | N = 2 | N = 7 | N = 6 |
| Grade 1 | 1 | 4 | 3 |
| Grade 2 | 1 | 0 | 2 |
| Unable to grade | 0 | 3 | 1 |
| Characteristics of reaction | |||
| Redness/itching | 1 | 3 | 5 |
| Rash | 1 | 0 | 1 |
| Edema | 1 | 2 | 1 |
| Hives | 0 | 1 | 0 |
| Infusion site pain | 1 | 3 | 2 |
| Swelling | 1 | 3 | 1 |
| Extravasation | 0 | 1 | 1 |
Abbreviations: 5HT3 serotonin 5-HT3 receptor antagonist, NK1 neurokinin 1 receptor antagonist, IV intravenous, CINV chemotherapy-induced nausea and vomiting
1Complete CINV response defined as no significant nausea, no vomiting, and no documented use of rescue therapy